Loading stock data…
$16.80-0.44 (-2.55%)
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $959,000↓ | $1.92M↑ | $1.75M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.74M↓ | -$39.67M↑ | -$42.49M↑ | -$44.81M↓ | -$37.12M |
| Net Income | -$52.79M↓ | -$38.26M↑ | -$41.23M↓ | -$38.44M↓ | -$35.93M |
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, whic...